Yahoo Finance Five Star Equities Issues New Research Reports on CHTP, ELN, ISIL and NVAX
Five Star Equities releases regular market updates so investors can stay ahead of the crowd and make the best investment decisions to maximize their returns. Take a few minutes to register with us free at www.FiveStarEquities.com and get exclusive access to our numerous stock reports.
Chelsea Therapeutics International Ltd. (NASDAQ:CHTP - News) shares declined 8.14 percent to close at $2.82 a share Monday. The stock traded between $2.71 and $3.07 on volume of 2.14 million shares traded. The company announced that the FDA “has identified certain technical deficiencies in the resubmission” of the New Drug Application for NORTHERA.
Get more information on Chelsea Therapeutics and free access to the in-depth equity report at:
www.FiveStarEquities.com/CHTP
Elan Corporation, plc (NYSE:ELN - News) shares gained 3.55 percent to close at $15.46 a share Monday. The stock traded between $15.32 and $15.92 on volume of 114.49 million shares traded. The company has agreed to be acquired by Perrigo Co. for approximately $8.6 billion. Shares of Elan have gained approximately 51.0 percent year-to-date.
Get more information on Elan and free access to the in-depth equity report at:
www.FiveStarEquities.com/ELN
Intersil Corp. (NASDAQ:ISIL - News) shares increased 4.54 percent to close at $9.21 a share Monday. The stock traded between $9.00 and $9.32 on volume of 2.15 million shares traded. The company announced rebalancing initiatives that include reducing its workforce by approximately 150 employees. Shares of Intersil have gained approximately 11.0 percent year-to-date.
Get more information on Intersil and free access to the in-depth equity report at:
www.FiveStarEquities.com/ISIL
Novavax, Inc. (NASDAQ:NVAX - News) shares increased 0.80 percent to close at $2.51 a share Monday. The stock traded between $2.50 and $2.63 on volume of 1.59 million shares traded. The company reported positive preclinical data for its virus-like particle (VLP) vaccine candidate against A(H7N9) influenza. Shares of Novavax have gained approximately 32.8 percent year-to-date.
Get more information on Novavax and free access to the in-depth equity report at:
www.FiveStarEquities.com/NVAX
Disclaimer: Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. We accept no liability for any losses arising from an investor's reliance on or use of this report. This report is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. Certain information included herein is forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. Such forward-looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. Five Star Equities has no financial relationship with any company whose stock is mentioned in this release.
Contact:
Five Star Equities
info@fivestarequities.com
